argenx reported positive topline results from the Phase 3 ADAPT OCULUS trial evaluating VYVGART (efgartigimod alfa and hyaluronidase-qvfc) in adults with ocular myasthenia gravis. The randomized, double-blind, placebo-controlled study (n=141) met its primary endpoint, showing a statistically significant improvement versus placebo in MGII patient-reported ocular scores at Week 4 (p=0.012). The company said the trial data will be presented at an upcoming medical meeting and will support a planned supplemental Biologics License Application submission to the FDA to expand the product label into ocular myasthenia gravis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief on February 26, 2026, and is solely responsible for the information contained therein.